Drugs / Levornidazole
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07033182 | Oct 2023 → Apr 2024 | anaerobic bacteria infectious disease, impaired renal function disease | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06828874 | May 2023 → Sep 2024 | infectious peritonitis | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levornidazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07033182 ↗ |
| Route | Intravenous | “intravenously guttae” NCT06828874 ↗ |